Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-01-11

AUTHORS

X. Palard-Novello, S. Querellou, M. Gouillou, A. Saraux, T. Marhadour, F. Garrigues, R. Abgral, P. Y. Salaün, V. Devauchelle-Pensec

ABSTRACT

PurposeTo evaluate the use of 18F-FDG PET/CT for the assessment of tocilizumab (TCZ) as first-line treatment in patients with polymyalgia rheumatica (PMR).MethodsPatients with PMR were prospectively enrolled in a multicentre clinical trial assessing TCZ therapy (the TENOR trial). The patients underwent FDG PET/CT at baseline, after the first infusion of TCZ (TCZ 1) and after the last infusion of TCZ (TCZ 3). Responses to treatment were evaluated in terms of the PMR activity score (PMR-AS), and the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) laboratory tests. Maximal standardized uptake value (SUVmax) was used for assessment of FDG uptake in regions usually affected in PMR (spinous processes, hips, shoulders, sternoclavicular region and ischial tuberosities). The Wilcoxon test was applied to evaluate the changes in parameters after the infusions and Spearman’s rank correlation test was applied to assess the correlations between SUVmax and PMR-AS, CRP and ESR.ResultsOf 21 patients included in the trial, 18 were evaluated. The median bioclinical parameter values decreased after TCZ 1 (PMR-AS from 38.2 to 15.7, CRP from 65.2 to 0.4 mg/l and ESR from 49 to 6.5 mm; all p < 0.05) as did the median SUVmax (from 5.8 to 5.2; p < 0.05). All values also decreased after TCZ 3 (PMR-AS from 38.2 to 3.9, CRP from 65.2 to 0.2, ESR from 49 to 2, and SUVmax from 5.8 to 4.7; p < 0.05). In a region-based analysis, all SUVmax were significantly reduced after TCZ 3, except the values for the cervical spinous processes and shoulder regions. With regard to correlations, few significant differences were found between ∆SUVmax and the other parameters including ∆PMR-AS, ∆CRP and ∆ESR in the patient-based and region-based analysis.ConclusionFDG uptake decreased significantly but moderately after TCZ therapy in PMR patients, and might reflect disease activity. More... »

PAGES

773-779

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-015-3287-z

DOI

http://dx.doi.org/10.1007/s00259-015-3287-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1052039261

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26753600


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multimodal Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polymyalgia Rheumatica", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tomography, X-Ray Computed", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France", 
          "id": "http://www.grid.ac/institutes/grid.411766.3", 
          "name": [
            "Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palard-Novello", 
        "givenName": "X.", 
        "id": "sg:person.01003201417.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003201417.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EA3878, GETBO, IFR148, Brest University, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.6289.5", 
          "name": [
            "Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France", 
            "EA3878, GETBO, IFR148, Brest University, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Querellou", 
        "givenName": "S.", 
        "id": "sg:person.01342720603.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342720603.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Investigation Centre (CIC) 1412, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Clinical Investigation Centre (CIC) 1412, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM), Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gouillou", 
        "givenName": "M.", 
        "id": "sg:person.01226236307.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226236307.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EA 2216, ESPRI 29, Brest University, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.6289.5", 
          "name": [
            "Department of Rheumatology, Brest University Hospital, Brest, France", 
            "EA 2216, ESPRI 29, Brest University, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saraux", 
        "givenName": "A.", 
        "id": "sg:person.0656357510.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656357510.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, Brest University Hospital, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.411766.3", 
          "name": [
            "Department of Rheumatology, Brest University Hospital, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marhadour", 
        "givenName": "T.", 
        "id": "sg:person.01235744144.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235744144.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Brest University Hospital, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.411766.3", 
          "name": [
            "Department of Radiology, Brest University Hospital, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garrigues", 
        "givenName": "F.", 
        "id": "sg:person.0721154165.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721154165.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EA3878, GETBO, IFR148, Brest University, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.6289.5", 
          "name": [
            "Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France", 
            "EA3878, GETBO, IFR148, Brest University, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abgral", 
        "givenName": "R.", 
        "id": "sg:person.01310147073.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310147073.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EA3878, GETBO, IFR148, Brest University, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.6289.5", 
          "name": [
            "Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France", 
            "EA3878, GETBO, IFR148, Brest University, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sala\u00fcn", 
        "givenName": "P. Y.", 
        "id": "sg:person.01021766527.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021766527.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EA 2216, ESPRI 29, Brest University, Brest, France", 
          "id": "http://www.grid.ac/institutes/grid.6289.5", 
          "name": [
            "Department of Rheumatology, Brest University Hospital, Brest, France", 
            "EA 2216, ESPRI 29, Brest University, Brest, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Devauchelle-Pensec", 
        "givenName": "V.", 
        "id": "sg:person.01160615110.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160615110.11"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10165-010-0382-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049095764", 
          "https://doi.org/10.1007/s10165-010-0382-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-006-0133-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037793914", 
          "https://doi.org/10.1007/s00259-006-0133-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-011-1830-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034643118", 
          "https://doi.org/10.1007/s00259-011-1830-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10067-014-2650-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001500332", 
          "https://doi.org/10.1007/s10067-014-2650-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-012-2179-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014721368", 
          "https://doi.org/10.1007/s00259-012-2179-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-014-0423-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049058267", 
          "https://doi.org/10.1186/s13075-014-0423-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10165-011-0581-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004547821", 
          "https://doi.org/10.1007/s10165-011-0581-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-01-11", 
    "datePublishedReg": "2016-01-11", 
    "description": "PurposeTo evaluate the use of 18F-FDG PET/CT for the assessment of tocilizumab (TCZ) as first-line treatment in patients with polymyalgia rheumatica (PMR).MethodsPatients with PMR were prospectively enrolled in a multicentre clinical trial assessing TCZ therapy (the TENOR trial). The patients underwent FDG PET/CT at baseline, after the first infusion of TCZ (TCZ 1) and after the last infusion of TCZ (TCZ 3). Responses to treatment were evaluated in terms of the PMR activity score (PMR-AS), and the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) laboratory tests. Maximal standardized uptake value (SUVmax) was used for assessment of FDG uptake in regions usually affected in PMR (spinous processes, hips, shoulders, sternoclavicular region and ischial tuberosities). The Wilcoxon test was applied to evaluate the changes in parameters after the infusions and Spearman\u2019s rank correlation test was applied to assess the correlations between SUVmax and PMR-AS, CRP and ESR.ResultsOf 21 patients included in the trial, 18 were evaluated. The median bioclinical parameter values decreased after TCZ 1 (PMR-AS from 38.2 to 15.7, CRP from 65.2 to 0.4\u00a0mg/l and ESR from 49 to 6.5\u00a0mm; all p\u2009<\u20090.05) as did the median SUVmax (from 5.8 to 5.2; p\u2009<\u20090.05). All values also decreased after TCZ 3 (PMR-AS from 38.2 to 3.9, CRP from 65.2 to 0.2, ESR from 49 to 2, and SUVmax from 5.8 to 4.7; p\u2009<\u20090.05). In a region-based analysis, all SUVmax were significantly reduced after TCZ 3, except the values for the cervical spinous processes and shoulder regions. With regard to correlations, few significant differences were found between \u2206SUVmax and the other parameters including \u2206PMR-AS, \u2206CRP and \u2206ESR in the patient-based and region-based analysis.ConclusionFDG uptake decreased significantly but moderately after TCZ therapy in PMR patients, and might reflect disease activity.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-015-3287-z", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "43"
      }
    ], 
    "keywords": [
      "C-reactive protein", 
      "PET/CT", 
      "first-line treatment", 
      "polymyalgia rheumatica", 
      "TCZ therapy", 
      "rank correlation test", 
      "maximal standardized uptake value", 
      "FDG PET/CT", 
      "assessment of tocilizumab", 
      "PMR activity score", 
      "multicentre clinical trial", 
      "standardized uptake value", 
      "region-based analysis", 
      "cervical spinous process", 
      "PMR-AS", 
      "ConclusionFDG uptake", 
      "PMR patients", 
      "disease activity", 
      "first infusion", 
      "last infusion", 
      "activity score", 
      "FDG uptake", 
      "Spearman rank correlation test", 
      "median SUVmax", 
      "clinical trials", 
      "tocilizumab", 
      "patients", 
      "uptake value", 
      "SUVmax", 
      "spinous process", 
      "infusion", 
      "therapeutic assessment", 
      "Wilcoxon test", 
      "shoulder region", 
      "rheumatica", 
      "CT", 
      "significant differences", 
      "therapy", 
      "treatment", 
      "correlation test", 
      "trials", 
      "laboratory tests", 
      "MethodsPatients", 
      "assessment", 
      "PurposeTo", 
      "uptake", 
      "baseline", 
      "scores", 
      "test", 
      "correlation", 
      "response", 
      "differences", 
      "protein", 
      "activity", 
      "AS", 
      "analysis", 
      "values", 
      "changes", 
      "regard", 
      "use", 
      "ESR", 
      "region", 
      "parameters", 
      "terms", 
      "process", 
      "parameter values"
    ], 
    "name": "Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment", 
    "pagination": "773-779", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1052039261"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-015-3287-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26753600"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-015-3287-z", 
      "https://app.dimensions.ai/details/publication/pub.1052039261"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:04", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_711.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-015-3287-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3287-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3287-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3287-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-015-3287-z'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      21 PREDICATES      113 URIs      98 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-015-3287-z schema:about N0a4b809b525b4b92a444da8bf81f44fd
2 N246170d4e3a64a5fa992302924d97427
3 N2effaa490eb34c6db5886dda393fcd10
4 N32a530834fcf4e8b8c28d9400d0137b6
5 N5519e4af614642f880c4748668d84986
6 N59c277fa86c445e2b27e1b7a7e679e20
7 N650aa8406a0b4e3499be965d8cf4c979
8 N705a663305314da69c594f6ba4320b44
9 N71b961ace41d4acbac38c5b8f3b40c05
10 N8c5e5494584243569810ea86c9a2a2de
11 N906c10a1de5c4ef3a1d78fd82cc4c6bf
12 Nc4f0c5f4e7c1431a8a6888a25e458467
13 Nd526dd68e76a406c93f83be096528aa2
14 Ne25c1d81294d45c3b4be4cdc8f7373df
15 Nedf9a5b436af41b5ac8028f70c7753a6
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author Nf725aaff5c724cfaa367f206b5341657
19 schema:citation sg:pub.10.1007/s00259-006-0133-3
20 sg:pub.10.1007/s00259-011-1830-0
21 sg:pub.10.1007/s00259-012-2179-8
22 sg:pub.10.1007/s10067-014-2650-y
23 sg:pub.10.1007/s10165-010-0382-7
24 sg:pub.10.1007/s10165-011-0581-x
25 sg:pub.10.1186/s13075-014-0423-2
26 schema:datePublished 2016-01-11
27 schema:datePublishedReg 2016-01-11
28 schema:description PurposeTo evaluate the use of 18F-FDG PET/CT for the assessment of tocilizumab (TCZ) as first-line treatment in patients with polymyalgia rheumatica (PMR).MethodsPatients with PMR were prospectively enrolled in a multicentre clinical trial assessing TCZ therapy (the TENOR trial). The patients underwent FDG PET/CT at baseline, after the first infusion of TCZ (TCZ 1) and after the last infusion of TCZ (TCZ 3). Responses to treatment were evaluated in terms of the PMR activity score (PMR-AS), and the C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) laboratory tests. Maximal standardized uptake value (SUVmax) was used for assessment of FDG uptake in regions usually affected in PMR (spinous processes, hips, shoulders, sternoclavicular region and ischial tuberosities). The Wilcoxon test was applied to evaluate the changes in parameters after the infusions and Spearman’s rank correlation test was applied to assess the correlations between SUVmax and PMR-AS, CRP and ESR.ResultsOf 21 patients included in the trial, 18 were evaluated. The median bioclinical parameter values decreased after TCZ 1 (PMR-AS from 38.2 to 15.7, CRP from 65.2 to 0.4 mg/l and ESR from 49 to 6.5 mm; all p < 0.05) as did the median SUVmax (from 5.8 to 5.2; p < 0.05). All values also decreased after TCZ 3 (PMR-AS from 38.2 to 3.9, CRP from 65.2 to 0.2, ESR from 49 to 2, and SUVmax from 5.8 to 4.7; p < 0.05). In a region-based analysis, all SUVmax were significantly reduced after TCZ 3, except the values for the cervical spinous processes and shoulder regions. With regard to correlations, few significant differences were found between ∆SUVmax and the other parameters including ∆PMR-AS, ∆CRP and ∆ESR in the patient-based and region-based analysis.ConclusionFDG uptake decreased significantly but moderately after TCZ therapy in PMR patients, and might reflect disease activity.
29 schema:genre article
30 schema:isAccessibleForFree false
31 schema:isPartOf N0f18a2faac614c1782d9e64a5aee588c
32 N45acf1d099e1430db84db49f1cd4a919
33 sg:journal.1297401
34 schema:keywords AS
35 C-reactive protein
36 CT
37 ConclusionFDG uptake
38 ESR
39 FDG PET/CT
40 FDG uptake
41 MethodsPatients
42 PET/CT
43 PMR activity score
44 PMR patients
45 PMR-AS
46 PurposeTo
47 SUVmax
48 Spearman rank correlation test
49 TCZ therapy
50 Wilcoxon test
51 activity
52 activity score
53 analysis
54 assessment
55 assessment of tocilizumab
56 baseline
57 cervical spinous process
58 changes
59 clinical trials
60 correlation
61 correlation test
62 differences
63 disease activity
64 first infusion
65 first-line treatment
66 infusion
67 laboratory tests
68 last infusion
69 maximal standardized uptake value
70 median SUVmax
71 multicentre clinical trial
72 parameter values
73 parameters
74 patients
75 polymyalgia rheumatica
76 process
77 protein
78 rank correlation test
79 regard
80 region
81 region-based analysis
82 response
83 rheumatica
84 scores
85 shoulder region
86 significant differences
87 spinous process
88 standardized uptake value
89 terms
90 test
91 therapeutic assessment
92 therapy
93 tocilizumab
94 treatment
95 trials
96 uptake
97 uptake value
98 use
99 values
100 schema:name Value of 18F-FDG PET/CT for therapeutic assessment of patients with polymyalgia rheumatica receiving tocilizumab as first-line treatment
101 schema:pagination 773-779
102 schema:productId N1ff2c75c9ba543c1bc23f99e6086e63e
103 N46ed2b837342420fb77c332fd6fd68bb
104 N9c58756fb80f4b8ea0e28a183becef9b
105 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052039261
106 https://doi.org/10.1007/s00259-015-3287-z
107 schema:sdDatePublished 2022-08-04T17:04
108 schema:sdLicense https://scigraph.springernature.com/explorer/license/
109 schema:sdPublisher Nc7504485d3a84541bd6a51f0bff8433e
110 schema:url https://doi.org/10.1007/s00259-015-3287-z
111 sgo:license sg:explorer/license/
112 sgo:sdDataset articles
113 rdf:type schema:ScholarlyArticle
114 N0a4b809b525b4b92a444da8bf81f44fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged, 80 and over
116 rdf:type schema:DefinedTerm
117 N0f18a2faac614c1782d9e64a5aee588c schema:volumeNumber 43
118 rdf:type schema:PublicationVolume
119 N1979f5dc218a42b0a67c8ef16aae29f8 rdf:first sg:person.0656357510.01
120 rdf:rest Ndb26241434b543e4a46bbf9c848bf593
121 N1d917efe5da44df7b82cc5579109c5d4 rdf:first sg:person.01226236307.73
122 rdf:rest N1979f5dc218a42b0a67c8ef16aae29f8
123 N1ff2c75c9ba543c1bc23f99e6086e63e schema:name dimensions_id
124 schema:value pub.1052039261
125 rdf:type schema:PropertyValue
126 N246170d4e3a64a5fa992302924d97427 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Radiopharmaceuticals
128 rdf:type schema:DefinedTerm
129 N297cea3d454240309e6fbecb2aa39360 rdf:first sg:person.01342720603.94
130 rdf:rest N1d917efe5da44df7b82cc5579109c5d4
131 N2effaa490eb34c6db5886dda393fcd10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Clinical Trials as Topic
133 rdf:type schema:DefinedTerm
134 N32a530834fcf4e8b8c28d9400d0137b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Polymyalgia Rheumatica
136 rdf:type schema:DefinedTerm
137 N45acf1d099e1430db84db49f1cd4a919 schema:issueNumber 4
138 rdf:type schema:PublicationIssue
139 N46ed2b837342420fb77c332fd6fd68bb schema:name pubmed_id
140 schema:value 26753600
141 rdf:type schema:PropertyValue
142 N5519e4af614642f880c4748668d84986 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Middle Aged
144 rdf:type schema:DefinedTerm
145 N59c277fa86c445e2b27e1b7a7e679e20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 N650aa8406a0b4e3499be965d8cf4c979 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Antibodies, Monoclonal, Humanized
150 rdf:type schema:DefinedTerm
151 N705a663305314da69c594f6ba4320b44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Tomography, X-Ray Computed
153 rdf:type schema:DefinedTerm
154 N706b8f7c115f4bc0a28e8da1be5ab95b rdf:first sg:person.01310147073.34
155 rdf:rest N70724ea74a6346c8a1d85744bc4187a8
156 N70724ea74a6346c8a1d85744bc4187a8 rdf:first sg:person.01021766527.49
157 rdf:rest N74b7ae97c3d0437bba0d45e0179dd410
158 N71b961ace41d4acbac38c5b8f3b40c05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Antirheumatic Agents
160 rdf:type schema:DefinedTerm
161 N74b7ae97c3d0437bba0d45e0179dd410 rdf:first sg:person.01160615110.11
162 rdf:rest rdf:nil
163 N8c5e5494584243569810ea86c9a2a2de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Fluorodeoxyglucose F18
165 rdf:type schema:DefinedTerm
166 N906c10a1de5c4ef3a1d78fd82cc4c6bf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Female
168 rdf:type schema:DefinedTerm
169 N9c58756fb80f4b8ea0e28a183becef9b schema:name doi
170 schema:value 10.1007/s00259-015-3287-z
171 rdf:type schema:PropertyValue
172 Nb0f79a098967470eaf602a9dd0c52cfa rdf:first sg:person.0721154165.73
173 rdf:rest N706b8f7c115f4bc0a28e8da1be5ab95b
174 Nc4f0c5f4e7c1431a8a6888a25e458467 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Positron-Emission Tomography
176 rdf:type schema:DefinedTerm
177 Nc7504485d3a84541bd6a51f0bff8433e schema:name Springer Nature - SN SciGraph project
178 rdf:type schema:Organization
179 Nd526dd68e76a406c93f83be096528aa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Humans
181 rdf:type schema:DefinedTerm
182 Ndb26241434b543e4a46bbf9c848bf593 rdf:first sg:person.01235744144.49
183 rdf:rest Nb0f79a098967470eaf602a9dd0c52cfa
184 Ne25c1d81294d45c3b4be4cdc8f7373df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Male
186 rdf:type schema:DefinedTerm
187 Nedf9a5b436af41b5ac8028f70c7753a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Multimodal Imaging
189 rdf:type schema:DefinedTerm
190 Nf725aaff5c724cfaa367f206b5341657 rdf:first sg:person.01003201417.71
191 rdf:rest N297cea3d454240309e6fbecb2aa39360
192 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
193 schema:name Medical and Health Sciences
194 rdf:type schema:DefinedTerm
195 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
196 schema:name Clinical Sciences
197 rdf:type schema:DefinedTerm
198 sg:journal.1297401 schema:issn 1619-7070
199 1619-7089
200 schema:name European Journal of Nuclear Medicine and Molecular Imaging
201 schema:publisher Springer Nature
202 rdf:type schema:Periodical
203 sg:person.01003201417.71 schema:affiliation grid-institutes:grid.411766.3
204 schema:familyName Palard-Novello
205 schema:givenName X.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01003201417.71
207 rdf:type schema:Person
208 sg:person.01021766527.49 schema:affiliation grid-institutes:grid.6289.5
209 schema:familyName Salaün
210 schema:givenName P. Y.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021766527.49
212 rdf:type schema:Person
213 sg:person.01160615110.11 schema:affiliation grid-institutes:grid.6289.5
214 schema:familyName Devauchelle-Pensec
215 schema:givenName V.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01160615110.11
217 rdf:type schema:Person
218 sg:person.01226236307.73 schema:affiliation grid-institutes:grid.7429.8
219 schema:familyName Gouillou
220 schema:givenName M.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226236307.73
222 rdf:type schema:Person
223 sg:person.01235744144.49 schema:affiliation grid-institutes:grid.411766.3
224 schema:familyName Marhadour
225 schema:givenName T.
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01235744144.49
227 rdf:type schema:Person
228 sg:person.01310147073.34 schema:affiliation grid-institutes:grid.6289.5
229 schema:familyName Abgral
230 schema:givenName R.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01310147073.34
232 rdf:type schema:Person
233 sg:person.01342720603.94 schema:affiliation grid-institutes:grid.6289.5
234 schema:familyName Querellou
235 schema:givenName S.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01342720603.94
237 rdf:type schema:Person
238 sg:person.0656357510.01 schema:affiliation grid-institutes:grid.6289.5
239 schema:familyName Saraux
240 schema:givenName A.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0656357510.01
242 rdf:type schema:Person
243 sg:person.0721154165.73 schema:affiliation grid-institutes:grid.411766.3
244 schema:familyName Garrigues
245 schema:givenName F.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721154165.73
247 rdf:type schema:Person
248 sg:pub.10.1007/s00259-006-0133-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037793914
249 https://doi.org/10.1007/s00259-006-0133-3
250 rdf:type schema:CreativeWork
251 sg:pub.10.1007/s00259-011-1830-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034643118
252 https://doi.org/10.1007/s00259-011-1830-0
253 rdf:type schema:CreativeWork
254 sg:pub.10.1007/s00259-012-2179-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014721368
255 https://doi.org/10.1007/s00259-012-2179-8
256 rdf:type schema:CreativeWork
257 sg:pub.10.1007/s10067-014-2650-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1001500332
258 https://doi.org/10.1007/s10067-014-2650-y
259 rdf:type schema:CreativeWork
260 sg:pub.10.1007/s10165-010-0382-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049095764
261 https://doi.org/10.1007/s10165-010-0382-7
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s10165-011-0581-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004547821
264 https://doi.org/10.1007/s10165-011-0581-x
265 rdf:type schema:CreativeWork
266 sg:pub.10.1186/s13075-014-0423-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049058267
267 https://doi.org/10.1186/s13075-014-0423-2
268 rdf:type schema:CreativeWork
269 grid-institutes:grid.411766.3 schema:alternateName Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France
270 Department of Radiology, Brest University Hospital, Brest, France
271 Department of Rheumatology, Brest University Hospital, Brest, France
272 schema:name Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France
273 Department of Radiology, Brest University Hospital, Brest, France
274 Department of Rheumatology, Brest University Hospital, Brest, France
275 rdf:type schema:Organization
276 grid-institutes:grid.6289.5 schema:alternateName EA 2216, ESPRI 29, Brest University, Brest, France
277 EA3878, GETBO, IFR148, Brest University, Brest, France
278 schema:name Department of Nuclear Medicine, Brest University Hospital, 2 Avenue FOCH, 26609, Brest Cedex, France
279 Department of Rheumatology, Brest University Hospital, Brest, France
280 EA 2216, ESPRI 29, Brest University, Brest, France
281 EA3878, GETBO, IFR148, Brest University, Brest, France
282 rdf:type schema:Organization
283 grid-institutes:grid.7429.8 schema:alternateName Clinical Investigation Centre (CIC) 1412, Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
284 schema:name Clinical Investigation Centre (CIC) 1412, Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...